Head and neck squamous cell carcinoma (HNSCC), the sixth most common cancer in the world, is widely represented as a heterogeneous tumor with more aggressive phenotypes.

Despite ongoing efforts over the past 4 decades, multidisciplinary treatments (surgery, radiotherapy, chemotherapy, target, or immunotherapy) have not sufficiently improved the 5-year survival rate of patients with these devastating diseases, especially those with advanced head and neck cancer who have locoregional lymph node metastases. Therefore, no matter in the field of clinical or basic research, more research is needed to obtain breakthrough progress, to realize the update and optimization of treatment guidelines in the field of head and neck cancer and the benign development of precision medicine.

The aim of this Special Issue is to provide the reader with a comprehensive insight as new evidence based on well-designed clinical studies, new discoveries in molecular pathology, and original new advances in genetics or epigenetics, especially in the field of tumor immune microenvironment of head and neck cancer. We welcome original research and review articles.

Potential topics include but are not limited to the following:

• New progress on cancer risk and early detection of head and cancer
• Improvement of quality of life and prevention of complications of head and neck cancer
• Clinical and basic studies on metastasis diseases of head and neck cancer
• Precancerous lesions and head and neck cancer
• Simultaneous or metachronous carcinoma in the head and neck region
• New discoveries in the field of EMT, autophagy, exosomes in HNSCC cells
• The mechanism mediating drug or radiotherapy resistance of patients with HNSCC
• The mechanism of immune escape based on tumor microenvironment of HNSCC
• Proliferation and cell death of HNSCC
• Hypoxia and metabolism of HNSCC
• New advances in the imaging and pathology of head and neck cancer
• Exploration of new treatments or modified methods for HNSCC,for example: local injection, photochemotherapy, etc.